MCC950

MCC950 is an inhibitor of NOD-like receptor protein 3 (NLRP3) inflammasome activation. It inhibits ATP-induced IL-1beta release in LPS-primed mouse bone marrow-derived macrophages (BMDMs, IC50 = 7.5 nM), as well as cytosolic LPS-induced IL-1beta release in Pam3CSK4-primed mouse BMDMs at 0.1 and 1 µM, indicating inhibition of both canonical and non-canonical NLRP3 inflammasome activation, respectively. MCC950 is selective for NLRP3 over NLRC4 and absent in melanoma 2 (AIM2) inflammasomes and does not inhibit LPS-induced NLRP3 priming in mouse BMDMs at 10 µM. It reduces ox-LDL-induced increases in caspase-1 activity and inhibits pyroptosis in THP-1 macrophages when used at a concentration of 1 µM. MCC950 (10 mg/kg) reduces myocardial fibrosis in mice following myocardial infarction induced by left coronary artery ligation. It improves forelimb grip strength and reduces spinal edema in a mouse model of spinal crush injury at the same dose.Formal Name: N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide. CAS Number: 210826-40-7. Synonyms: CP 456,773. Molecular Formula: C20H24N2O5S. Formula Weight: 404.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 5 mg/ml, DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml, Ethanol: 0.5 mg/ml. SMILES: O=S(NC(NC1=C(CCC2)C2=CC3=C1CCC3)=O)(C4=CC(C(C)(O)C)=CO4)=O. InChi Code: InChI=1S/C20H24N2O5S/c1-20(2,24)14-10-17(27-11-14)28(25,26)22-19(23)21-18-15-7-3-5-12(15)9-13-6-4-8-16(13)18/h9-11,24H,3-8H2,1-2H3,(H2,21,22,23). InChi Key: HUUSXLKCTQDPGL-UHFFFAOYSA-N.